cms.bioaccessla.com

Category: First-in-Human

  • Clínica Colonial Santiago: The NCT Campus String Is Not the ISP File

    Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ISP, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Clínica Colonial Santiago as a bioaccess® client.

    If you searched Clinica Colonial Santiago first-in-human, Clinica Colonial Chile clinical trial, Clinica Colonial CRO, or “go direct Clínica Colonial Santiago,” you followed a campus string ClinicalTrials.gov still publishes. Clínica Colonial in Santiago, Chile, is a real named hospital/clinic-campus string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ISP file.

    bioaccess®’s position is simple and it is not adversarial: the hospital is the site. The First-in-Human CRO still owns ISP, accredited ethics, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the hospital still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named Santiago Clínica Colonial campus. It is DISTINCT from Clínica Santa María Santiago, Hospital San José Santiago, and Hospital Luis Tisné Santiago. Sharing Santiago metro is not a license to collapse them. Clínica Colonial is not Clínica Santa María. Clínica Colonial is not Hospital Luis Tisné.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

    Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    Cite canonical ALL n=9 and DEVICE n=9. Do not clone Clínica Santa María Santiago or Hospital Luis Tisné onto this slug. Example device NCT IDs use the first 3 of the device list; full device list remains in the backlog.

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this hospital as a client site.

    That is the leak: a founder searching Clínica Colonial Santiago first-in-human finds ALL n=9 (DEVICE n=9) without finding ISP. A named hospital/clinic campus is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named hospital can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the hospital can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the hospital is not built to own for an investigational device:

    • ISP. Instituto de Salud Pública (ISP) authorizes studies and investigational-device import in Chile. Live Chile blogs already put a typical ISP review in a band of about 30 business days. Commercial ISP registration (30–90 days) is a different file. An Ethical-Scientific Committee under Law 20.120 still has to sit. A hallway conversation on this campus is not that stack. We will not invent PAHO/WHO Level 4 standing for ISP. A hallway conversation at Clínica Colonial is not a Clínica Santa María file and is not a Hospital Luis Tisné file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. We will not invent a campus-only premium here.
    • ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How ISP actually works (the short version)

    Use clinical-trials-chile. Instituto de Salud Pública (ISP) authorizes studies and investigational-device import. Live Chile blogs already put a typical ISP review in a band of about 30 business days. Commercial ISP registration in a 30–90 day band is a different file — do not put trial authorization and commercial registro on one Gantt labeled “Chile.” An Ethical-Scientific Committee under Law 20.120 still has to sit. We will not invent PAHO/WHO Level 4 standing for ISP on this page.

    Ask for a protocol-specific calendar. A hospital email is not ISP clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

    Do not smear the hospital

    Clínica Colonial Santiago is a serious named Chilean campus on the public registry. ALL n=9 and DEVICE n=9 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, IB, ICF, insurance, and the ISP / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract Clínica Colonial Santiago directly for a device FIH?

    You can try. The hospital can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ISP applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this hospital. We will not invent that claim. This page intercepts the search; it does not claim the studies.

    Is this the same page as Clínica Santa María Santiago or Hospital Luis Tisné?

    No. clinica-santa-maria-santiago-fih is already live. hospital-luis-tisne-santiago-fih is a distinct Santiago campus in this leftover batch. This page is Clínica Colonial only.

    Did bioaccess® run NCT05695989?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Santiago sibling (do not merge): Clínica Santa María Santiago.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Clinical trial insurance for medical device studies in Latin America

    Sponsors still ask the same question before every Latin American device study start: what clinical trial insurance do we need for ethics, import, and a second country? The answer is a country-snapshot checklist — territory, named insureds, language, runoff — not a hallway promise that “we’re global.”

    I am Julio Martinez-Clark, CEO of bioaccess®. This hub is the missing checklist page that satellite posts already pointed at. It is general information, not insurance, legal, or regulatory advice. Confirm current ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates here. We do not claim a named carrier as a signed bioaccess® partner on this page. No patient data. No unpublished client. Always bioaccess®.

    The CRO is not the carrier

    Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

    • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
    • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
    • CRO. Protocol, IB, ICF, ethics and national-authority packet, investigational importer, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. Eligibility of foreign data is not FDA clearance.

    Mixing those jobs is how a startup buys a U.S. product-liability rider, emails an English PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

    The country-snapshot checklist

    Insurance documentation usually sits in the ethics / national-authority packet, not as a post-approval formality. Before first submission, write five lines and make the certificate match them:

    1. Territory. Name every country on the protocol. A Delaware HoldCo certificate that never names Panama, El Salvador, Chile, or Brazil is decoration.
    2. Named insureds. Sponsor entity legal name as it appears on the CTA and ICF. Add site and principal investigator as additional insureds when the committee requires it.
    3. Language. Spanish for Spanish-speaking committees; Portuguese for CEP/CONEP in Brazil. An English-only certificate is a classic resubmission. See Spanish or Portuguese insurance certificates for LATAM ethics.
    4. Period and runoff. Policy period through last-patient last-visit plus the protocol follow-up window. Confirm claims-made vs occurrence and any runoff the committee or CTA expects. Do not invent a pan-regional day count here.
    5. Claims-notice language. Must sit next to the SAE clock, not against it. The person who opens the SAE notice should know who opens the claims notice.

    We will not invent a per-participant dollar limit on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together before the packet goes in.

    Local admitted paper vs controlled master

    Two workable patterns — confirm which the reviewing body will stamp:

    • Local admitted policy in the study country, with certificates that name the site and PI.
    • Controlled master that can issue local certificates (or notarized Spanish/Portuguese summaries) for each country on the protocol.

    A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. When country 2 sits, the move is an endorsement or a new certificate — not a new CRO contract that pretends to be a binder. That intercept lives on adding a second LATAM country endorsement.

    Country snapshots (use live hubs; confirm on filing day)

    These are operator snapshots for insurance timing, not rate cards:

    • Panama (MINSA / CNBI). Ethics review through institutional bioethics committees registered with CNBI. Published ethics typically 3–5 weeks on the Panama hub; insurance exhibits belong in that packet. Per-patient cost bands already published there: about USD 12,000–22,000. Spanish certificate language is the usual ask.
    • El Salvador (SRS / CNEIS). Parallel SRS and CNEIS review; country hub publishes a 30–60 day startup band. Financial responsibility for participant injury still belongs in the ethics packet before initiation. Keep trial insurance off the commercial registro track.
    • Chile (ISP). Fast-corridor country with efficient ethics + ISP pathways. Plan Spanish certificates and additional insureds before the ethics date, same as the rest of the corridor.
    • Costa Rica. Corridor speed with concentrated sites. Same five-line checklist as above.
    • Brazil (ANVISA / CEP). Portuguese certificate of insurance is not optional stationery for CEP/CONEP. Use the Brazil clinical-trials hub for clocks — do not invent medians here.
    • Mexico (COFEPRIS). Keep trial liability separate from registro sanitario. Territory must name Mexico before the ethics packet goes in.
    • Colombia (INVIMA). Public line unchanged: bioaccess® still runs clinical trials in Colombia and owns CRO-in-Colombia; INVIMA commercial registration remains. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. A Bogotá ethics packet still wants financial responsibility for participant injury — that does not flip the FIH recommendation line.

    What bioaccess® owns after you have a quote

    • Regulatory-fit geography — not country tourism.
    • Protocol, IB, ICF, and the ethics / national-authority packet with insurance documents in the same stack — not a parallel founder email.
    • Importer of record and device accountability. A binder does not import the investigational product.
    • Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
    • Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

    The firm was founded in 2010. Public device case studies already on site (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. Public copy mentioning a $10M Sangria™ trial policy describes CRO coordination, not a SKU or rate we invent here.

    Common failures that stall ethics

    • English-only certificate in a Spanish or Portuguese committee folder.
    • Territory that lists “worldwide” but never names the study country.
    • Product-liability or general-liability rider treated as trial liability.
    • Site MSA “insurance included” with no sponsor trial form.
    • Country 2 added to the protocol with no endorsement calendar.
    • Policy period that ends before last-patient last-visit plus follow-up.

    Related reading

    Need the insurance exhibit sequenced with your LATAM FIH packet? bioaccess® runs the trial under ISO 14155 and can introduce a specialty carrier. We do not underwrite. Contact Julio Martinez-Clark, Co-Founder & CEO, at jmclark@bioaccessla.com or +1 (954) 903-7210.

    Frequently asked questions

    Does bioaccess® sell clinical trial insurance?

    No. We are the First-in-Human CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

    What should a LATAM clinical trial insurance certificate show?

    Territory naming every study country, correct named insureds (and additional insureds when required), Spanish or Portuguese language when the committee asks, policy period through LPLV plus follow-up / runoff as required, and claims-notice language that can sit next to the SAE clock.

    Is this the same article as the Spanish/Portuguese certificate page?

    No. That page is the language intercept for the clerk who stamps the exhibit. This hub is the country-snapshot checklist (territory, named insureds, language, runoff). The second-country page is the endorsement intercept. Distinct slugs. Same rule: the CRO runs the trial; a carrier writes the paper.

    Can a U.S. product-liability policy cover a LATAM device FIH?

    Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

    When do we add insurance for a second LATAM country?

    Before the second ethics packet goes in. Ask whether the master can certificate the new country; if not, start local admitted paper in time for that ethics date. See the endorsement page.

  • El Salvador first-in-human cost and timeline vs the United States

    Boards keep asking how much a first-in-human medical device trial in El Salvador costs compared with the United States, and how long startup actually takes. Those are two questions. One is a published country clock. The other is a study-specific quote. Mixing them into one invented total is how diligence slides go soft.

    I am Julio Martinez-Clark, CEO of bioaccess®. This is an El Salvador country spotlight grounded in the live clinical trials in El Salvador hub, the fast-track FIH corridor post, and the sibling cost page that already covers Panama and El Salvador together. It is not a quote. Confirm budgets and calendars against your protocol.

    What “vs the United States” usually buys

    When sponsors say a U.S. FIH is too expensive, they usually mean three stacked costs:

    1. Time to first patient — site contracting, IRB sequencing, and treating first implant as a United States-only problem.
    2. Site and per-patient economics — hospital fees, investigator fees, and visit complexity priced from the schedule of events.
    3. Evidence quality for later FDA use — ISO 14155 discipline and a 21 CFR § 812.28 design, or you bought speed you cannot spend.

    An El Salvador investigation is not a discount coupon on FDA clearance. It is a second evidence calendar that can run while the U.S. path is still being built. Eligibility of foreign data for FDA submission and review is not a guarantee of clearance or approval.

    Published El Salvador clocks (investigation only)

    The live El Salvador hub already publishes a 30–60 day study-startup band via parallel review by the Superintendencia de Regulación Sanitaria (SRS) and the Comité Nacional de Ética de la Investigación en Salud (CNEIS) on one digital platform. That band is investigation authorization plus ethics — not commercial registro.

    SRS replaced the former Dirección Nacional de Medicamentos (DNM) in August 2024 under the Ley de la Superintendencia de Regulación Sanitaria (7 August 2024). Ethics stays centralized at CNEIS. The live step-by-step FIH guide already names the SRS-CNEIS-ES digital platform and the user manual issued 17 November 2025. Use that manual. Do not invent article numbers from reforms you have not opened.

    On the corridor clock published in the startup guide, El Salvador sits with Panama, Chile, and Costa Rica in the 15–45 day activation tier for the fast corridor as a whole. Treat those as indicative operator bands. Ask for a study-specific calendar before you put a single date on a board slide.

    Cost: what is published vs what must be quoted

    Two cost facts already live on bioaccess® pages — and that is where I stop inventing:

    • The El Salvador hub already publishes roughly 60% cost savings versus equivalent U.S. programs, plus a dollarized (U.S. dollar) economy. That is orientation from the country page, not a formal study for your Class III implant.
    • Inside the fast corridor, El Salvador is the cost leader on hospital and site fees versus Panama. The corridor post states that gap in plain operator language. Panama remains the proven sprinter on activation; El Salvador undercuts it on site economics.

    I will not invent a dollar program total, a weekly burn, or a “typical U.S. per-patient” figure on this page. If your U.S. sites have not returned real bids, leave that cell blank. Blank is more honest than a blogger’s invented average. For how LATAM FIH money actually splits — site pass-throughs, CRO professional fees, third-party costs — start from the FIH Latin America budget guide.

    What drives cost and time in El Salvador

    Same four stages as the rest of the region; El Salvador compresses them when the file is clean:

    1. Preparation and Spanish package. Protocol, investigator’s brochure, informed consent, case report forms, and the insurance certificate the committee will stamp. Rework, not review, is the usual delay.
    2. CNEIS cadence. Centralized national ethics, not a tourism of local IRBs.
    3. SRS investigation authorization. Parallel with ethics on the published digital path — not a sequential hope.
    4. Investigational import. Units for research only. Do not put a cousin commercial registro number on FIH freight. That pattern burns weeks at customs and contaminates both tracks.

    Enrollment is a separate model. El Salvador is a small market. Activation in weeks means nothing if patient flow for your indication is thin. Model enrollment from real San Salvador site flow, prequalify backup sites, and keep the startup clock distinct from first-patient-in.

    Keep the trial file off the commercial holder track

    Cost discipline in El Salvador starts with two dossiers:

    • Trial file: Spanish protocol package, CNEIS ethics, SRS investigation authorization, investigational labeling, ISO 14155 monitoring plan, import story for study units only.
    • Registro / holder file (optional, later): commercial market access. Different petition. Different success criteria. Already spelled out on CNEIS/SRS trial authorization vs registro.

    If the same person owns both without two importers and two success criteria, you do not have an El Salvador plan. You have a hope that erases the calendar advantage the hub already publishes.

    Insurance and import are line items, not footnotes

    Ethics packets still want financial responsibility for participant injury documented before initiation — usually a Spanish certificate. Product liability is not clinical-trial liability. A U.S. master that never names El Salvador fails the exhibit. Budget the certificate with the CRO and a licensed broker before you present “LATAM is cheaper.” See the insurance hub and the language intercept on Spanish/Portuguese certificates.

    Public case work already on the site (including Avantec Vascular / Sangria™) treated insurance placement and investigational import as operational workstreams — not as bioaccess® underwriting. We do not invent premiums from those pages.

    Colombia note (do not flip the public line)

    Colombia remains a strong market-access geography and a historical FIH geography for bioaccess®. The public line still stands: INVIMA clinical-trial approval timelines have become unpredictable, so bioaccess® does not currently recommend Colombia for new first-in-human execution. Use El Salvador, Panama, Chile, or the Dominican Republic when the protocol needs a lead investigation desk — and keep INVIMA registro on the commercial track.

    Board slide that survives diligence

    • Evidence column. El Salvador CNEIS/SRS, investigational importer, § 812.28 owner, ISO 14155 TMF owner.
    • Published bands only. 30–60 day startup; corridor cost-leader note vs Panama; ~60% vs U.S. orientation from the hub — then a study-specific quote.
    • U.S. column as real bids — or blank.
    • Commercial column (optional). Holder / IOR countries on the market-access track. Already-cleared launch is a different SKU from FIH.

    Related reading

    Planning an El Salvador FIH file? bioaccess® is a US-headquartered, LATAM-native First-in-Human CRO. To discuss CNEIS/SRS sequencing, investigational import, and a study-specific cost/timeline quote — contact Julio Martinez-Clark, Co-Founder & CEO, at jmclark@bioaccessla.com or +1 (954) 903-7210.

    Frequently asked questions

    How much does a first-in-human medical device trial in El Salvador cost compared with the United States?

    Use published orientation, not an invented total. The El Salvador hub already cites roughly 60% cost savings versus equivalent U.S. programs and a dollarized economy. Inside the fast corridor, hospital and site fees run below Panama’s. Program totals still need a proposal priced from your schedule of events. Leave any U.S. comparator blank until named U.S. sites return real bids.

    How long does El Salvador FIH startup take?

    The country hub publishes 30–60 days via parallel SRS and CNEIS review. The regional startup clock groups El Salvador with the fast corridor at a 15–45 day activation tier. Confirm a study-specific calendar. Activation is not first-patient-in.

    Is El Salvador cheaper than Panama for FIH?

    On hospital and site fees, yes in bioaccess® operator experience — that is why the corridor post calls El Salvador the cost leader. Panama remains the documented extreme on activation speed. Pick on indication fit and patient flow, not the clock alone.

    Is the trial authorization the same as DNM/SRS registro?

    No. Investigation and commercial registro are separate files. Merging them creates rework that erases the published calendar advantage.

    Does the FDA accept clinical data from El Salvador?

    Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets the GCP conditions in that rule, including SRS authorization and CNEIS ethics approval. Eligibility is not clearance or approval.

  • Latin America vs. Australia for FIH Medical Device Trials: Operational Realities Beyond the Tax Rebate

    Founders comparing FIH medical device clinical trials Latin America vs Australia usually start with one slide: Australia’s 43.5% Research & Development Tax Incentive. That offset is real for eligible entities. It is also not the whole operating picture. Once you price site access, timezone friction, principal-investigator bandwidth, and whether the file can survive an FDA foreign-data conversation under 21 CFR 812.28, the Australia-versus-Latin-America choice stops being a rebate math problem and becomes a calendar-and-execution problem.

    I am Julio Martinez-Clark, CEO of bioaccess®. This brief is the operational cut that sits beside our published Australian R&D rebate math and the live Australia comparison hub. It is not tax advice. Confirm current R&DTI rules with your Australian advisers. Confirm study-specific clocks with a proposal.

    1. Why founders look to Australia

    Australia earned its reputation with early-phase sponsors for four reasons that still matter for medical devices:

    • No US IND/IDE as a precondition to start. Under the Clinical Trial Notification (CTN) pathway, many device investigations can open without a TGA clinical pre-review of the protocol. English-language HREC review and site governance still apply. The CTN is not a free pass; it is a different gate than a US Investigational Device Exemption.
    • The 43.5% refundable R&D tax offset for eligible companies with aggregated turnover under A$20M (figures in force for FY2025–26 and FY2026–27 on our rebate article). Clinical-trial spend can sit outside the standard A$4M annual refund cap when the activities qualify. That is financing, not a 43.5% invoice discount.
    • English end-to-end. Protocol, consent, monitoring reports, and source can stay in English. For US regulatory affairs teams that have never run a Spanish ethics packet, that alone can feel like risk reduction.
    • Hospital-grade sites and ISO 14155 culture. Australian private HRECs (including Bellberry-style pathways) and public-hospital National Mutual Acceptance processes are documented. Experienced device CROs and hospital implant sites exist. For non-surgical wearables or diagnostic devices that fit a Phase I unit model, the Australian infrastructure is mature.

    None of that is marketing fluff. If your board already has an Australian subsidiary, a booked HREC slot, and a PI who has room, Australia can be the right first country. The question is whether that combination is what you actually have — or what the slide assumes you will have after six more months of contracting.

    2. Hidden friction: saturation, timezone, and travel

    The rebate slide rarely shows the three frictions US medtech operators hit after the LOI:

    Site and PI saturation. Australia’s device FIH market is smaller than the marketing deck implies. A handful of high-volume hospitals and implant-capable investigators take a disproportionate share of early-feasibility work. When several US startups chase the same orthopedic, cardiovascular, or neurotech wards in Melbourne, Sydney, or Brisbane, start-up stops being “6–8 weeks to HREC” and becomes a queue for investigator time, theatre slots, and competing protocols. Drug Phase I units are abundant; Class III implant bandwidth is not.

    Fourteen to sixteen hours from US Eastern Time. Same-day PI questions turn into next-calendar-day loops. Monitoring visits, serious-adverse-event triage, and FDA Pre-Sub prep calls stack against Australian business hours. Your clinical lead in Boston wakes up to yesterday’s answers. That is manageable for a single Phase I cohort. It is expensive when the device needs iterative implant feedback, imaging reads, and sponsor–CRO–PI huddles in the first ten patients.

    Travel and presence cost. A US engineering or medical director who needs to be in theatre for the first cases buys long-haul flights, jet lag, and limited week blocks. Latin America FIH hubs that sit on or near US Eastern Time (Panama City is the clearest example on our public hubs) let the same person leave Miami in the morning and stand in the OR the same afternoon. That is not tourism. It is how you keep design engineers inside the first-implant feedback loop without burning a week of runway per trip.

    Gross cash versus rebate recovery. As our rebate math article already states: you fund the Australian gross cost now and recover part of it after year-end lodgement — only if an eligible Australian entity exists, aggregated turnover clears the test (connected entities count), and AusIndustry accepts the activities. Rebate-advance lenders exist; they charge. On a gross cash basis, bioaccess® program experience still puts Latin America roughly 35–45% below Australia; after a fully captured rebate the gap can narrow to about 5–15%, and in some programs reverse. Treat that as published orientation, not a guarantee for your Class III cohort.

    Entity and compliance overhead. Standing up the Australian subsidiary, registering R&D activities, and defending the claim is real work. Teams that treat the 43.5% figure as a coupon often under-budget the local tax and legal stack that makes the coupon collectible.

    3. The Latin America counter-proposition

    Latin America’s offer for first-in-human and early-feasibility device work is not “cheaper Australia.” It is a different operating system built around calendar proximity to US teams, investigator engagement, and investigation desks that do not require a US IDE to start.

    Published start-up bands. On bioaccess® country hubs and FIH guides, coordinated programs in lead geographies such as Panama commonly show ethics in about 3–5 weeks and roughly 6–8 weeks to first patient when the Spanish package, insurance certificate, and investigational import are ready. El Salvador’s public language for CNEIS ethics plus SRS clinical-investigation authorization sits in a 30–60 day band. Those are investigation clocks — not commercial registro. Ask for a study-specific Gantt; do not paste a hub median onto a board slide as a promise.

    Same-timezone US proximity. Panama City runs on US Eastern Time. Miami is a short flight. For US sponsors, that means PI calls land in the same workday, monitoring can be planned without a 16-hour offset, and the medical director can attend early implants without a Pacific crossing. Other LATAM hubs add Spanish-language depth and surgical volume; the timezone argument is strongest where clocks align with US Eastern or Central.

    PI engagement and surgical volume. Early-feasibility device work needs investigators who already operate in the indication and hospitals that will treat a novel implant as a protocol, not a legal crisis. Latin American tertiary centers in published FIH geographies have run ISO 14155-style device investigations with bilingual teams. The operating move is named PI and named ward in the feasibility deliverable — not a country flag on a map.

    Where we point new FIH work. Prefer Latin America destinations that publish usable investigation frameworks for high-risk devices — Panama (MINSA / CNBI under Ley 84 and Decreto Ejecutivo No. 21 of 2026), El Salvador (CNEIS / SRS), and other hubs already on the clinical-trials hub — when the protocol needs a lead investigation desk. Colombia remains a strong market-access geography. The public line still stands: INVIMA clinical-trial approval timelines have become unpredictable, so bioaccess® does not currently recommend Colombia for new first-in-human execution. Keep INVIMA on the commercial registration track. Do not flip that sentence.

    What LATAM is not. It is not a reason to skip ISO 14155 monitoring, device accountability, or a coherent preclinical narrative. Thin trial master files buy investor slides and FDA friction. It is also not automatic commercial sale: trial authorization and sanitary registration are different desks in every country we work.

    4. Data compatibility for FDA — 21 CFR 812.28

    Foreign clinical data can support an IDE or a device marketing application when the investigation meets 21 CFR 812.28 (final rule, 83 FR 7386, 21 February 2018). Eligibility is not clearance. Design for the rule; do not treat geography as a substitute for GCP.

    Section 812.28(a) requires, in substance:

    1. Good clinical practice — design, conduct, monitoring, auditing, recording, analysis, and reporting that keep data credible and protect subjects, including independent ethics-committee review before initiation and documented freely given informed consent. FDA has stated that conformance with ISO 14155:2020 will generally satisfy the GCP requirement of 812.28.
    2. Supporting information in 812.28(b) for significant-risk devices — investigators and sites; protocol and results; identity of the investigational device to the US device or a detailed comparison; IEC identity; consent, monitoring, and investigator GCP training.
    3. FDA can validate the data through onsite inspection or other means if the agency deems it necessary. A file that cannot be inspected is not an 812.28 file.

    Australia’s English TMF can feel easier to hand an inspector. That advantage disappears if the Australian site never had bandwidth to enroll, or if the sponsor never built monitoring and device accountability. Latin America files written in Spanish at the ethics desk still need English-capable source, EDC, and accountability that survive an FDA conversation — plus a Pre-Sub / Q-Sub before you lock endpoints when the Panama or El Salvador cohort is meant to support a later US IDE (written feedback in 75 calendar days is the usual Pre-Sub clock).

    Parallel clause already on our FDA-acceptance materials: 21 CFR 814.15 for foreign data in PMA applications. Plan for 812.28(a), not the residual 812.28(e) lifeline.

    How to choose this week

    1. Write two columns: Australia (entity + HREC + named PI + gross cash + rebate recovery timing) versus Latin America lead jurisdiction (ethics desk + investigational importer + 6–8 week band + US timezone plan).
    2. Price presence. Count flights and same-day PI loops for the first ten patients, not only per-patient fees.
    3. Name the 812.28 owner before first implant — TMF, device accountability, consent elements aligned to 21 CFR 50.25 if FDA use is intended.
    4. Keep commercial registro off the FIH critical path. Market-access holder strategy is a different SKU from investigation authorization.

    If your Australian path already has a free PI and a funded subsidiary, run the rebate math honestly and go. If you are still shopping for investigator time against a 14–16 hour offset, put Latin America on the same slide with published clocks from the clinical-trials hub and the Australia compare page — and keep Colombia on market access, not as the default new-FIH recommendation.

    Related: Australia vs Latin America R&D tax incentive, compare Australia, and LATAM clinical trials. For a study-specific calendar, bring protocol stage, device risk class, intended US filing, and whether the investigational unit matches the US unit.

  • Hcor São Paulo: The NCT Campus String Is Not the ANVISA File

    Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANVISA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Hcor São Paulo as a bioaccess® client.

    If you searched Hcor Sao Paulo first-in-human, Hospital do Coracao Sao Paulo clinical trial, Hcor CRO, or “go direct Hcor São Paulo,” you followed a campus string ClinicalTrials.gov still publishes. Hcor in São Paulo, Brazil, is a real named hospital-campus string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANVISA file.

    bioaccess®’s position is simple and it is not adversarial: the hospital is the site. The First-in-Human CRO still owns ANVISA, CEP / CONEP, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the hospital still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named São Paulo Hcor campus. It is DISTINCT from other live São Paulo campuses (Hospital São Paulo UNIFESP, Instituto do Coração HCFMUSP, Medcin, Beneficência Portuguesa — do not near-dup collapse Beneficência). Sharing São Paulo metro is not a license to collapse them. Hcor is not InCor HCFMUSP. Hcor is not Beneficência Portuguesa. Hcor is not Hospital São Paulo UNIFESP.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

    Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    • Hcor (São Paulo, Brazil) — canonical NCT string: ALL interventional n=17; DEVICE n=1. Example NCT IDs: NCT05398497.

    Cite canonical ALL n=17 and DEVICE n=1. Do not clone InCor HCFMUSP, Beneficência Portuguesa, or Hospital São Paulo UNIFESP onto this slug.

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this hospital as a client site.

    That is the leak: a founder searching Hcor São Paulo first-in-human finds ALL n=17 (DEVICE n=1) without finding ANVISA. A named hospital campus is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named hospital can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the hospital can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the hospital is not built to own for an investigational device:

    • ANVISA. Device investigations sit under RDC 837/2023 (dossier in Portuguese: IB, protocol, ICF, insurance, GMP evidence). A hallway conversation at this campus is not that dossier. A hallway conversation at Hcor is not an InCor HCFMUSP file and is not a Beneficência Portuguesa file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. We will not invent a campus-only premium here.
    • ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How ANVISA actually works (the short version)

    Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.

    Ask for a protocol-specific calendar. A hospital email is not ANVISA clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

    Do not smear the hospital

    Hcor São Paulo is a serious named Brazilian campus on the public registry. ALL n=17 and DEVICE n=1 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, IB, ICF, insurance, and the ANVISA / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract Hcor São Paulo directly for a device FIH?

    You can try. The hospital can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this hospital. We will not invent that claim. This page intercepts the search; it does not claim the studies.

    Is this the same page as Instituto do Coração HCFMUSP or Beneficência Portuguesa?

    No. instituto-coracao-hcfmusp-fih is already live. Beneficência Portuguesa São Paulo is already live — do not near-dup merge. This page is Hcor only.

    Did bioaccess® run NCT05398497?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. São Paulo sibling (do not merge): Instituto do Coração HCFMUSP.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Federal University of Bahia Salvador: The NCT Campus String Is Not the ANVISA File

    Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANVISA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Federal University of Bahia Salvador as a bioaccess® client.

    If you searched Federal University of Bahia Salvador first-in-human, UFBA clinical trial, Universidade Federal da Bahia CRO, or “go direct Federal University of Bahia Salvador,” you followed a campus string ClinicalTrials.gov still publishes. Federal University of Bahia (UFBA) in Salvador, Brazil, is a real named university-campus string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANVISA file.

    bioaccess®’s position is simple and it is not adversarial: the university is the site. The First-in-Human CRO still owns ANVISA, CEP / CONEP, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the university still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named Salvador UFBA campus (alias includes Hospital Universitário Professor Edgard Santos / HUPES-UFBA). It is DISTINCT from live idor-regional-bahia-salvador-fih and nucleo-oncologia-bahia-salvador-fih. Sharing Salvador / Bahia is not a license to collapse them. UFBA is not IDOR Regional Bahia. UFBA is not Núcleo de Oncologia da Bahia.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

    Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    • Federal University of Bahia (Salvador, Brazil) — canonical NCT string: ALL interventional n=18; DEVICE n=3. Example NCT IDs: NCT01968512, NCT02152267, NCT07633444.

    Cite canonical ALL n=18 and DEVICE n=3. Do not clone IDOR Regional Bahia or Núcleo de Oncologia da Bahia onto this slug.

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this university as a client site.

    That is the leak: a founder searching Federal University of Bahia Salvador first-in-human finds ALL n=18 (DEVICE n=3) without finding ANVISA. A named university campus is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named university can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the university can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the university is not built to own for an investigational device:

    • ANVISA. Device investigations sit under RDC 837/2023 (dossier in Portuguese: IB, protocol, ICF, insurance, GMP evidence). A hallway conversation at this campus is not that dossier. A hallway conversation at UFBA is not an IDOR Regional Bahia file and is not a Núcleo de Oncologia da Bahia file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. We will not invent a campus-only premium here.
    • ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How ANVISA actually works (the short version)

    Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.

    Ask for a protocol-specific calendar. A hospital email is not ANVISA clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

    Do not smear the hospital

    Federal University of Bahia Salvador is a serious named Brazilian campus on the public registry. ALL n=18 and DEVICE n=3 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, IB, ICF, insurance, and the ANVISA / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract Federal University of Bahia Salvador directly for a device FIH?

    You can try. The university can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this university. We will not invent that claim. This page intercepts the search; it does not claim the studies.

    Is this the same page as IDOR Regional Bahia or Núcleo de Oncologia da Bahia Salvador?

    No. idor-regional-bahia-salvador-fih and nucleo-oncologia-bahia-salvador-fih are already live. This page is Federal University of Bahia Salvador only.

    Did bioaccess® run NCT01968512?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Salvador sibling (do not merge): IDOR Regional Bahia Salvador.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • IADT Buenos Aires: The NCT Campus String Is Not the ANMAT File

    Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANMAT, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim IADT Buenos Aires as a bioaccess® client.

    If you searched IADT Buenos Aires first-in-human, IADT Argentina clinical trial, IADT CRO, or “go direct IADT Buenos Aires,” you followed a campus string ClinicalTrials.gov still publishes. IADT in Buenos Aires, Argentina, is a real named institute/center string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANMAT file.

    bioaccess®’s position is simple and it is not adversarial: the institute is the site. The First-in-Human CRO still owns ANMAT, accredited ethics, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the institute still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named Buenos Aires IADT campus. It is DISTINCT from live Psoriahue (CMS 96118), IDIM (CMS 96119), Centro Medico Arsema (batch 55), and FLENI Buenos Aires. Sharing Buenos Aires / Argentina is not a license to collapse them. IADT is not Psoriahue. IADT is not IDIM. IADT is not FLENI.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

    Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    • IADT (Buenos Aires, Argentina) — canonical NCT string: ALL interventional n=19; DEVICE n=1. Example NCT IDs: NCT04061733.

    Cite canonical ALL n=19 and DEVICE n=1. Do not clone Psoriahue, IDIM, Arsema, or FLENI onto this slug.

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this institute as a client site.

    That is the leak: a founder searching IADT Buenos Aires first-in-human finds ALL n=19 (DEVICE n=1) without finding ANMAT. A named institute is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named institute can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the institute can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the institute is not built to own for an investigational device:

    • ANMAT. Argentina’s national medicines and devices authority (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is the file a sponsor actually needs. A hallway conversation on this campus is not that file. A published statutory target on the trial side is 90 business days and the clock pauses for RFIs. Trial authorization and commercial registro are separate petitions. A hallway conversation at IADT is not a Psoriahue file, not an IDIM file, and not a FLENI file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. We will not invent a campus-only premium here.
    • ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How ANMAT actually works (the short version)

    Use live bioaccess® Argentina / ANMAT pages for the full pathway. Trial authorization and commercial registro are different petitions. Do not put both on one Gantt labeled “Argentina.” A published statutory target on the trial side is on the order of 90 business days and pauses for RFIs; ask for a protocol-specific calendar rather than treating an NCT row as start-up.

    Ask for a protocol-specific calendar. A hospital email is not ANMAT clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

    Do not smear the hospital

    IADT is a serious named Buenos Aires campus on the public registry. ALL n=19 and DEVICE n=1 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, IB, ICF, insurance, and the ANMAT / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract IADT Buenos Aires directly for a device FIH?

    You can try. The institute can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANMAT applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this institute. We will not invent that claim. This page intercepts the search; it does not claim the studies.

    Is this the same page as Psoriahue, IDIM, or FLENI Buenos Aires?

    No. Psoriahue is CMS 96118. IDIM is CMS 96119. FLENI Buenos Aires is already live from batch 56. This page is IADT only.

    Did bioaccess® run NCT04061733?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. CABA sibling (do not merge): FLENI Buenos Aires.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Fundacion Oftalmologica De Santander: The NCT Campus String Is Not the INVIMA File

    Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current INVIMA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Fundacion Oftalmologica De Santander as a bioaccess® client.

    If you searched Fundacion Oftalmologica De Santander first-in-human, FOSCAL clinical trial, Fundacion Oftalmologica Santander CRO, or “go direct Fundacion Oftalmologica De Santander,” you followed a campus string ClinicalTrials.gov still publishes. Fundacion Oftalmologica De Santander in Santander, Colombia, is a real named foundation-campus string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the INVIMA file.

    bioaccess®’s position is simple and it is not adversarial: the foundation is the site. The First-in-Human CRO still owns INVIMA, accredited ethics, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the foundation still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named Santander Fundacion Oftalmologica De Santander campus. It is not Fundación CTIC Bogotá, not Fundación Reumatología Fernando Chalem Bogotá, and not a Bogotá merge. Sharing a Fundación name is not a license to collapse them. Fundacion Oftalmologica De Santander is not CTIC. Fundacion Oftalmologica De Santander is not Fernando Chalem.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

    Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    • Fundacion Oftalmologica De Santander (Santander, Colombia) — canonical NCT string: ALL interventional n=20; DEVICE n=1. Example NCT IDs: NCT05883943.

    Cite canonical ALL n=20 and DEVICE n=1. Do not clone CTIC or Fernando Chalem onto this slug. Colombia NEW-FIH public line stays unchanged (leftover_lib COLOMBIA_P).

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this foundation as a client site.

    That is the leak: a founder searching Fundacion Oftalmologica De Santander first-in-human finds ALL n=20 (DEVICE n=1) without finding INVIMA. A named foundation is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named foundation can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the foundation can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the foundation is not built to own for an investigational device:

    • INVIMA. INVIMA is the national file for an investigational device in Colombia. Resolución 8430/1993 still sits on the ethics and research side of that stack. A hallway conversation on this campus is not the INVIMA dossier. Resolución 2378 does not govern device clinical trials — see the live country pages rather than importing a drug-GCP resolution onto a device file. A hallway conversation at Fundacion Oftalmologica De Santander is not a CTIC Bogotá file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. We will not invent a campus-only premium here.
    • ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How INVIMA actually works (the short version)

    Use CRO in Colombia. Published comparison already on the Panama country page: Colombia ethics typically 4–6 weeks; per-patient $15,000–$25,000. bioaccess® still runs clinical trials in Colombia — local entity, INVIMA clocks in-country. We pick the country the device needs. A hospital email in Montería is not INVIMA clearance.

    Ask for a protocol-specific calendar. A hospital email is not INVIMA clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

    Do not smear the hospital

    Fundacion Oftalmologica De Santander is a serious named Colombian campus on the public registry. ALL n=20 and DEVICE n=1 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator. Colombia NEW-FIH recommendation stays unchanged.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, IB, ICF, insurance, and the INVIMA / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract Fundacion Oftalmologica De Santander directly for a device FIH?

    You can try. The foundation can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your INVIMA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this foundation. We will not invent that claim. This page intercepts the search; it does not claim the studies.

    Is this the same page as Fundación CTIC Bogotá?

    No. fundacion-ctic-bogota-fih is already live. This page is Fundacion Oftalmologica De Santander only.

    Did bioaccess® run NCT05883943?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Colombia sibling (do not merge): Fundación CTIC Bogotá.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Universidade Federal Fluminense Niterói: The NCT Campus String Is Not the ANVISA File

    Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANVISA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Universidade Federal Fluminense Niterói as a bioaccess® client.

    If you searched Universidade Federal Fluminense Niteroi first-in-human, UFF Niteroi clinical trial, Universidade Federal Fluminense CRO, or “go direct Universidade Federal Fluminense Niterói,” you followed a campus string ClinicalTrials.gov still publishes. Universidade Federal Fluminense in Niterói, Brazil, is a real named university-campus string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANVISA file.

    bioaccess®’s position is simple and it is not adversarial: the university is the site. The First-in-Human CRO still owns ANVISA, CEP / CONEP, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the university still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named Niterói UFF campus. It is DISTINCT from live universidade-federal-fluminense-nova-friburgo-fih (Nova Friburgo — different city) and from complexo-hospitalar-niteroi-fih. Sharing UFF / Niterói is not a license to collapse them. UFF Niterói is not UFF Nova Friburgo. UFF Niterói is not Complexo Hospitalar Niterói.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

    Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    • Universidade Federal Fluminense (Niterói, Brazil) — canonical NCT string: ALL interventional n=21; DEVICE n=3. Example NCT IDs: NCT03687047, NCT04512677, NCT06967649.

    Cite canonical ALL n=21 and DEVICE n=3. Do not clone Nova Friburgo UFF or Complexo Hospitalar Niterói onto this slug.

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this university as a client site.

    That is the leak: a founder searching Universidade Federal Fluminense Niterói first-in-human finds ALL n=21 (DEVICE n=3) without finding ANVISA. A named university campus is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named university can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the university can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the university is not built to own for an investigational device:

    • ANVISA. Device investigations sit under RDC 837/2023 (dossier in Portuguese: IB, protocol, ICF, insurance, GMP evidence). A hallway conversation at this campus is not that dossier. A hallway conversation at UFF Niterói is not a Nova Friburgo file and is not a Complexo Hospitalar Niterói file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. We will not invent a campus-only premium here.
    • ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How ANVISA actually works (the short version)

    Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.

    Ask for a protocol-specific calendar. A hospital email is not ANVISA clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

    Do not smear the hospital

    Universidade Federal Fluminense Niterói is a serious named Brazilian campus on the public registry. ALL n=21 and DEVICE n=3 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, IB, ICF, insurance, and the ANVISA / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract Universidade Federal Fluminense Niterói directly for a device FIH?

    You can try. The university can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this university. We will not invent that claim. This page intercepts the search; it does not claim the studies.

    Is this the same page as UFF Nova Friburgo or Complexo Hospitalar Niterói?

    No. universidade-federal-fluminense-nova-friburgo-fih and complexo-hospitalar-niteroi-fih are already live. This page is Universidade Federal Fluminense Niterói only.

    Did bioaccess® run NCT03687047?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Distinct sibling (do not merge): Universidade Federal Fluminense Nova Friburgo.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Federal University of Santa Maria: The NCT Campus String Is Not the ANVISA File

    Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANVISA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Federal University of Santa Maria as a bioaccess® client.

    If you searched Federal University of Santa Maria first-in-human, UFSM clinical trial, Universidade Federal de Santa Maria CRO, or “go direct Federal University of Santa Maria,” you followed a campus string ClinicalTrials.gov still publishes. Federal University of Santa Maria (UFSM) in Santa Maria, Brazil, is a real named university-campus string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANVISA file.

    bioaccess®’s position is simple and it is not adversarial: the university is the site. The First-in-Human CRO still owns ANVISA, CEP / CONEP, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the university still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named Santa Maria UFSM campus (Brazil). It is DISTINCT from live clinica-santa-maria-santiago-fih (Chile — different country, different regulator). It is not Hospital de Clínicas Porto Alegre / HCPA and not Federal University of São Carlos. Sharing a Santa Maria name is not a license to collapse Chile and Brazil. UFSM is not Clínica Santa María Santiago. UFSM is not HCPA.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

    Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    • Federal University of Santa Maria (Santa Maria, Brazil) — canonical NCT string: ALL interventional n=25; DEVICE n=5. Example NCT IDs: NCT02088138, NCT02600182, NCT03154970.

    Cite canonical ALL n=25 and DEVICE n=5. Do not clone Clínica Santa María Santiago or HCPA onto this slug. Example device NCT IDs use the first 3 of the device list; full device list remains in the backlog.

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this university as a client site.

    That is the leak: a founder searching Federal University of Santa Maria first-in-human finds ALL n=25 (DEVICE n=5) without finding ANVISA. A named university campus is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named university can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the university can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the university is not built to own for an investigational device:

    • ANVISA. Device investigations sit under RDC 837/2023 (dossier in Portuguese: IB, protocol, ICF, insurance, GMP evidence). A hallway conversation at this campus is not that dossier. A hallway conversation at UFSM Santa Maria Brazil is not a Clínica Santa María Santiago Chile file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. We will not invent a campus-only premium here.
    • ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How ANVISA actually works (the short version)

    Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.

    Ask for a protocol-specific calendar. A hospital email is not ANVISA clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

    Do not smear the hospital

    Federal University of Santa Maria is a serious named Brazilian campus on the public registry. ALL n=25 and DEVICE n=5 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, IB, ICF, insurance, and the ANVISA / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract Federal University of Santa Maria directly for a device FIH?

    You can try. The university can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this university. We will not invent that claim. This page intercepts the search; it does not claim the studies.

    Is this the same page as Clínica Santa María Santiago?

    No. clinica-santa-maria-santiago-fih is the Chile campus under ISP. This page is Federal University of Santa Maria (Brazil / ANVISA) only.

    Did bioaccess® run NCT02088138?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Distinct Chile sibling (do not merge): Clínica Santa María Santiago.

    Julio G. Martinez-Clark, CEO · bioaccess®